Investigational drug · Phase 3
TB-PPD
Also called: Purified Protein Derivative of Tuberculin
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Tuberculosis, Latent Tuberculosis Infection.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
32
Any phase or sponsor naming "TB-PPD"
First trial start
2023
Aug 3, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TB-PPD", any sponsor or status.
- Phase 211
Conditions studied
As listed on its trial records.
- Tuberculosis
- Latent Tuberculosis Infection
Approved drugs for the same conditions: Tuberculosis · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "TB-PPD" as an intervention, largest first.
- TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy)Pivotal-lookingCompleted
Johns Hopkins UniversityAcademic, hospital or other
NCT00107887 · 17,415 participants · Start Jun 2005 · Primary completion Dec 2010
Drug: INH preventive therapy; TST (tuberculin skin test) · For: Tuberculosis; HIV Infections
Sites: Rio de Janeiro, Brazil
- Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion ProteinPivotal-lookingCompleted
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Industry
NCT05746611 · 7,500 participants · Start Apr 17, 2023 · Primary completion May 13, 2024
Drug: Recombinant Mycobacterium tuberculosis fusion protein for injection; TB-PPD was injected · For: Latent Tuberculosis Infection
Sites: Liuzhou, China
- Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TBPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT06568484 · 2,530 participants (planned) · Start May 8, 2026 · Primary completion Jul 2027
Drug: Bedaquiline; Levofloxacin · For: Tuberculosis, Latent
Sites: Ulaanbaatar, Mongolia; Lima, Peru; Mbeya, Tanzania · 8 sites in all
- Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)Pivotal-lookingCompleted
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Industry
NCT02795260 · 1,802 participants · Start May 2016 · Primary completion Oct 2016
Drug: Bacillus Calmette - Guerin; placebo of Bacillus Calmette - Guerin · For: Tuberculosis
- Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and AbovePivotal-lookingRecruiting
Chengdu CoenBiotech Co., LtdIndustry
NCT07152639 · 1,784 participants (planned) · Start Aug 9, 2025 · Primary completion May 1, 2026
Drug: 5μg/ml EEC; 5 unit(U) EC and 1 more · For: Tuberculosis
Sites: Beijing, China; Hunan, China; Liuzhou, China · 8 sites in all
- A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSIPivotal-lookingCompleted
Statens Serum InstitutAcademic, hospital or other
NCT01642888 · 1,190 participants · Start Sep 2012 · Primary completion Sep 2014
Drug: C-Tb; 2 T.U. Tuberculin PPD RT 23 SSI · For: Tuberculosis
Sites: Port Elizabeth, South Africa; Benoni, South Africa; Pretoria, South Africa · 9 sites in all
- Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 AllergenPivotal-lookingCompleted
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Industry
NCT02623556 · 1,090 participants (planned) · Start Dec 2015 · Primary completion Mar 2018
Drug: ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm; ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm · For: Tuberculosis
Sites: Wuxi, China; Shanghai, China
- Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65Pivotal-lookingCompleted
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Industry
NCT02389322 · 1,044 participants · Start Mar 2015 · Primary completion Jul 2015
Drug: 5μg/ml ESAT6-CFP10; 10μg/ml ESAT6-CFP10 and 2 more · For: Tuberculosis
Sites: Jurong, China
- Comparison of Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb vs Tuberculin PPD RT23 SSIPivotal-lookingCompleted
Statens Serum InstitutAcademic, hospital or other
NCT01631266 · 979 participants · Start Jul 2012 · Primary completion Oct 2014
Drug: C-Tb; 2 T.U. Tuberculin PPD RT 23 SSI · For: Tuberculosis
Sites: Barakaldo, Spain; Barcelona, Spain; Lugo, Spain · 13 sites in all
- QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.Pivotal-lookingCompleted
Hospital Universitari de BellvitgeAcademic, hospital or other
NCT01223534 · 871 participants · Start Jul 2010 · Primary completion Feb 2016
Drug: Preventive treatment with Isoniazid.; Preventive treatment with Isoniazid · For: Latent Tuberculosis Infection
Sites: L'Hospitalet de Llobregat, Barcelona, Spain
Newest research
PubMed records naming it or its code names, newest first.
- Diagnostic value of interferon-γ release assay in patients with COPD complicated with pulmonary tuberculosis.
Rong Y, Wang H, Su Y, et al. · BMC Infect Dis 2025
- Evaluation of the cross-immunity between Mycobacterium tuberculosis and Mycobacterium abscessus in vitro.
Xu D, Gu Y, Li G, et al. · BMC Microbiol 2025
- Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy population: a randomized, blind, parallel controlled phase III clinical study.
Ding X, Du W, Liu Q, et al. · BMC Infect Dis 2024
- Efficacy and Safety of Intralesional Immunotherapy with Tuberculin Purified Protein Derivative among Cutaneous Wart Patients.
Shrestha SB, Bhusal M, Jwarchan J, et al. · J Nepal Health Res Counc 2023
- Long-term economic evaluation of the recombinant Mycobacterium tuberculosis fusion protein (EC) test for the diagnosis of Mycobacterium tuberculosis infection.
Diao S, Liu Z, Liu D, et al. · Front Pharmacol 2023
- Recombinant mycobacterium tuberculosis fusion protein for diagnosis of mycobacterium tuberculosis infection: a short-term economic evaluation.
Liu Z, Diao S, Zeng L, et al. · Front Public Health 2023
Also in development for Tuberculosis
- BCGPhase 38 trials
ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis
- MTBVACBBV169Phase 32 trials
Biofabri, S.L · Tuberculosis, Tuberculosis (TB)
- DelamanidPhase 22 trials
WestVac Biopharma Co., Ltd. · Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
- BNT164a1Phase 21 trial
BioNTech SE · Tuberculosis
- BNT164b1Phase 21 trial
BioNTech SE · Tuberculosis
- BTZ-043Phase 21 trial
GSK · Tuberculosis
- GSK3036656Phase 21 trial
GSK · Tuberculosis
- JDB0131Phase 21 trial
WestVac Biopharma Co., Ltd. · Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.